Skip to main content
NASDAQ:ACHL

Achilles Therapeutics Competitors

$13.01
-0.69 (-5.04 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.01
$14.49
50-Day Range N/A
52-Week Range
$12.63
$18.95
Volume8,510 shs
Average Volume103,331 shs
Market Capitalization$528.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Achilles Therapeutics (NASDAQ:ACHL) Vs. IMCR, SEER, IBRX, BCAB, CGEM, and EWTX

Should you be buying ACHL stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Achilles Therapeutics, including Immunocore (IMCR), Seer (SEER), ImmunityBio (IBRX), BioAtla (BCAB), Cullinan Oncology (CGEM), and Edgewise Therapeutics (EWTX).

Immunocore (NASDAQ:IMCR) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Immunocore and Achilles Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Achilles Therapeutics10402.60

Immunocore presently has a consensus target price of $54.3333, indicating a potential upside of 32.84%. Achilles Therapeutics has a consensus target price of $21.20, indicating a potential upside of 62.95%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Immunocore.

Profitability

This table compares Immunocore and Achilles Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Achilles TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Immunocore and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Achilles TherapeuticsN/AN/AN/AN/AN/A

Summary

Achilles Therapeutics beats Immunocore on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Seer and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Achilles TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Seer and Achilles Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Achilles TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and Achilles Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Achilles Therapeutics10402.60

Seer currently has a consensus target price of $66.3333, suggesting a potential upside of 130.72%. Achilles Therapeutics has a consensus target price of $21.20, suggesting a potential upside of 62.95%. Given Seer's higher possible upside, analysts clearly believe Seer is more favorable than Achilles Therapeutics.

Summary

Achilles Therapeutics beats Seer on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares ImmunityBio and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Achilles TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares ImmunityBio and Achilles Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Achilles TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ImmunityBio and Achilles Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Achilles Therapeutics10402.60

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 64.58%. Achilles Therapeutics has a consensus target price of $21.20, suggesting a potential upside of 62.95%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Achilles Therapeutics.

Summary

ImmunityBio beats Achilles Therapeutics on 2 of the 3 factors compared between the two stocks.

Achilles Therapeutics (NASDAQ:ACHL) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Achilles Therapeutics and BioAtla's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles TherapeuticsN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares Achilles Therapeutics and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Achilles TherapeuticsN/AN/AN/A
BioAtlaN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Achilles Therapeutics and BioAtla, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achilles Therapeutics10402.60
BioAtla00403.00

Achilles Therapeutics currently has a consensus price target of $21.20, suggesting a potential upside of 62.95%. BioAtla has a consensus price target of $62.75, suggesting a potential upside of 30.73%. Given Achilles Therapeutics' higher possible upside, equities research analysts plainly believe Achilles Therapeutics is more favorable than BioAtla.

Cullinan Oncology (NASDAQ:CGEM) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and Achilles Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology00403.00
Achilles Therapeutics10402.60

Cullinan Oncology presently has a consensus price target of $48.75, suggesting a potential upside of 60.10%. Achilles Therapeutics has a consensus price target of $21.20, suggesting a potential upside of 62.95%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Cullinan Oncology.

Valuation & Earnings

This table compares Cullinan Oncology and Achilles Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
Achilles TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Cullinan Oncology and Achilles Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Achilles TherapeuticsN/AN/AN/A

Edgewise Therapeutics (NASDAQ:EWTX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Edgewise Therapeutics and Achilles Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
Achilles TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Edgewise Therapeutics and Achilles Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Achilles Therapeutics10402.60

Edgewise Therapeutics presently has a consensus price target of $34.25, suggesting a potential upside of 30.13%. Achilles Therapeutics has a consensus price target of $21.20, suggesting a potential upside of 62.95%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Edgewise Therapeutics.

Valuation & Earnings

This table compares Edgewise Therapeutics and Achilles Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
Achilles TherapeuticsN/AN/AN/AN/AN/A

Summary

Achilles Therapeutics beats Edgewise Therapeutics on 2 of the 3 factors compared between the two stocks.


Achilles Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Immunocore logo
IMCR
Immunocore
1.3$40.90-1.2%$1.76 billionN/A0.00News Coverage
SEER
Seer
1.1$28.75-11.2%$1.75 billionN/A0.00Earnings Announcement
Analyst Report
Gap Down
IBRX
ImmunityBio
1.7$15.19-8.2%$1.66 billionN/A0.00Gap Down
BioAtla logo
BCAB
BioAtla
1.7$48.00-2.7%$1.62 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$30.45-6.7%$1.33 billionN/A0.00
EWTX
Edgewise Therapeutics
1.8$26.32-0.5%$1.25 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.04-4.1%$1.15 billionN/A0.00News Coverage
Gap Down
KNTE
Kinnate Biopharma
1.7$23.52-0.4%$1.02 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$26.46-1.4%$923.53 millionN/A0.00
CNTB
Connect Biopharma
1.7$15.40-6.3%$885.56 millionN/A0.00News Coverage
STEM
Stem
0.0$18.20-7.4%$872.65 millionN/A0.00News Coverage
Gap Down
Pharming Group logo
PHAR
Pharming Group
0.0$13.00-1.0%$833.86 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.56-0.1%$791.88 millionN/A0.00Upcoming Earnings
Analyst Report
Vor Biopharma logo
VOR
Vor Biopharma
1.6$21.30-10.7%$790.91 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$10.97-3.1%$737.33 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$27.57-6.3%$735.95 millionN/A0.00
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.28-4.6%$709.40 millionN/A0.00News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$19.19-4.0%$697.13 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$12.27-0.2%$578.47 millionN/A0.00Gap Up
Inventiva logo
IVA
Inventiva
1.4$14.00-2.5%$540.82 millionN/A0.00
VACC
Vaccitech plc American Depositary Shares
0.3$14.40-5.8%$490.52 millionN/A0.00
MIGI
Mawson Infrastructure Group
0.0$0.95-0.5%$471.73 millionN/A0.00
BMEA
Biomea Fusion
1.7$15.88-3.1%$456.84 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$14.05-1.3%$442.98 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Gap Down
VECT
VectivBio
1.6$12.97-3.0%$441.18 millionN/A0.00Analyst Report
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.54-7.8%$428.70 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.47-0.6%$420.34 millionN/A0.00News Coverage
RAIN
Rain Therapeutics
1.3$15.91-3.1%$413.17 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.5$10.11-4.6%$405.59 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.35-0.1%$385.67 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$8.59-8.8%$369.36 millionN/A0.00
HOWL
Werewolf Therapeutics
0.3$12.91-0.6%$355.53 millionN/A0.00
PRTG
Portage Biotech
0.0$27.58-1.2%$333.25 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$9.69-4.9%$296.40 millionN/A0.00News Coverage
Gap Down
IMPL
Impel NeuroPharma
0.3$14.29-2.9%$277.44 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.36-7.5%$270.42 millionN/A-2.51Gap Down
RPHM
Reneo Pharmaceuticals
2.0$11.15-11.8%$269.95 millionN/A0.00Analyst Report
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.41-0.2%$241.62 millionN/A-2.35Earnings Announcement
News Coverage
VINC
Vincerx Pharma
1.0$16.50-0.0%$230.74 millionN/A0.00Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$7.10-3.2%$176.80 millionN/A0.00Analyst Downgrade
News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$24.99-15.5%$173.61 millionN/A0.00Upcoming Earnings
LBPH
Longboard Pharmaceuticals
1.9$9.28-4.4%$156.99 millionN/A0.00High Trading Volume
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$6.80-5.3%$130.35 millionN/A0.00Gap Down
GANX
Gain Therapeutics
1.7$9.78-0.3%$110.82 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$5.60-6.3%$107.51 millionN/A0.00Upcoming Earnings
LGVN
Longeveron
0.3$5.30-0.9%$100.47 millionN/A0.00Upcoming Earnings
News Coverage
UPC
Universe Pharmaceuticals
0.0$3.23-2.2%$70.25 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$16.86-1.5%$65.89 millionN/A0.00Earnings Announcement
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$5.34-2.1%$53.72 millionN/A0.00
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$9.19-3.6%$47.55 millionN/A0.00Upcoming Earnings
Analyst Report
Gap Down
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.